| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2023 | 284.62% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 09/13/2023 | 284.62% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/10/2023 | 284.62% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 05/16/2023 | 284.62% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 03/10/2023 | 207.69% | Maxim Group | → $16 | Initiates Coverage On | → Buy |
| 10/10/2022 | -42.31% | HC Wainwright & Co. | → $3 | Assumes | → Buy |
| 07/08/2022 | -42.31% | Wedbush | → $3 | Initiates Coverage On | → Outperform |
| 03/16/2022 | -61.54% | HC Wainwright & Co. | $4 → $2 | Maintains | Neutral |
| 03/16/2022 | -23.08% | RBC Capital | $5 → $4 | Maintains | Sector Perform |
| 08/20/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 08/16/2021 | — | Berenberg | Downgrades | Buy → Hold | |
| 08/16/2021 | -23.08% | HC Wainwright & Co. | $6 → $4 | Maintains | Neutral |
| 08/13/2021 | -3.85% | RBC Capital | $6 → $5 | Maintains | Sector Perform |
| 08/13/2021 | -42.31% | Morgan Stanley | $5 → $3 | Downgrades | Equal-Weight → Underweight |
| 03/17/2021 | 53.85% | RBC Capital | $10 → $8 | Maintains | Sector Perform |
| 12/29/2020 | 92.31% | RBC Capital | $40 → $10 | Downgrades | Outperform → Sector Perform |
| 12/16/2020 | 553.85% | Morgan Stanley | $39 → $34 | Maintains | Equal-Weight |
| 12/16/2020 | 611.54% | Berenberg | → $37 | Initiates Coverage On | → Buy |
| 06/22/2020 | 476.92% | HC Wainwright & Co. | → $30 | Initiates Coverage On | → Neutral |
| 04/21/2020 | 765.38% | Baird | → $45 | Initiates Coverage On | → Outperform |
| 04/15/2020 | 650% | Morgan Stanley | $36 → $39 | Maintains | Equal-Weight |
| 03/27/2020 | 592.31% | Morgan Stanley | $23 → $36 | Maintains | Equal-Weight |
| 10/28/2019 | 342.31% | JP Morgan | → $23 | Initiates Coverage On | → Neutral |
| 10/28/2019 | 342.31% | Morgan Stanley | → $23 | Initiates Coverage On | → Equal-Weight |
| 10/28/2019 | 534.62% | RBC Capital | → $33 | Initiates Coverage On | → Outperform |
What is the target price for Aprea Therapeutics (APRE)?
The latest price target for Aprea Therapeutics (NASDAQ: APRE) was reported by HC Wainwright & Co. on November 1, 2023. The analyst firm set a price target for $20.00 expecting APRE to rise to within 12 months (a possible 284.62% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aprea Therapeutics (APRE)?
The latest analyst rating for Aprea Therapeutics (NASDAQ: APRE) was provided by HC Wainwright & Co., and Aprea Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Aprea Therapeutics (APRE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aprea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aprea Therapeutics was filed on November 1, 2023 so you should expect the next rating to be made available sometime around November 1, 2024.
Is the Analyst Rating Aprea Therapeutics (APRE) correct?
While ratings are subjective and will change, the latest Aprea Therapeutics (APRE) rating was a reiterated with a price target of $0.00 to $20.00. The current price Aprea Therapeutics (APRE) is trading at is $5.20, which is within the analyst's predicted range.